IRAK4-IN-1
Modify Date: 2024-01-11 12:41:11
IRAK4-IN-1 structure
|
Common Name | IRAK4-IN-1 | ||
|---|---|---|---|---|
| CAS Number | 1820787-94-7 | Molecular Weight | 337.42 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H23N5O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IRAK4-IN-1IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. |
| Name | IRAK4-IN-1 |
|---|
| Description | IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with an IC50 of 7 nM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 7 nM (IRAK4)[1] |
| In Vitro | The in vitro metabolic stability profiles of IRAK4-IN-1 (Compound 23) is measured, with EC50 of 2300 nM for the rat whole blood (RWB) [1]. |
| In Vivo | Oral pharmacokinetic studies of IRAK4-IN-1 (Compound 23) show it to have high bioavailability of 73% and low plasma clearance(Clp=22 mL/min/kg) leading to a reasonable half-life of 1.3 h[1]. |
| Animal Admin | Rats[1] In the TLR driven in vivo model, female Lewis rats are dosed with either vehicle or IRAK4-IN-1 (Compound 23; 3, 10, 30, and 100 mg/kg; p.o.) dosed at 1 h prior to stimulation with Resiquimod, R848 (5 mg/kg, IP). At 1.5 h post R848 stimulation, blood samples are obtained from the animals and cytokine levels are measured. |
| References |
| Molecular Formula | C19H23N5O |
|---|---|
| Molecular Weight | 337.42 |
| Appearance of Characters | off white solid |
| Storage condition | -20℃ |